ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2303

Trends in Gout and Rheumatoid Arthritis Hospitalizations in Canada from 2000-2011

Sharan K. Rai1,2, J. Antonio Avina-Zubieta2,3, Natalie McCormick2,4, Mary A. De Vera2,5, Diane Lacaille2,6, Eric C. Sayre2 and Hyon K. Choi7,8, 1Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, 2Arthritis Research Canada, Richmond, BC, Canada, 3Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, 4Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, 5Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, 6Medicine, University of British Columbia, Vancouver, BC, Canada, 7Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 8Arthritis Research Canada, Vancouver, BC, Canada

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: gout, Health care cost and rheumatoid arthritis (RA), Joint replacement

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Metabolic and Crystal Arthropathies - Poster II: Epidemiology and Mechanisms of Disease

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Gout and rheumatoid arthritis (RA) are the two most common forms of inflammatory arthritis worldwide. As hospitalizations for both conditions lead to substantial health resource use, contemporary inpatient trends and associated costs may provide important benchmarks of disease burden. However, relevant data are limited. We evaluated contemporary hospitalization trends for gout and RA in a Canadian general population context.

Methods: We used PopulationData BC, a population-based dataset spanning the entire Canadian province of British Columbia. We included patients at least 18 years of age who were hospitalized from 2000-2011 with a principal diagnosis of either gout (ICD-9-CM 274 or ICD-10-CA M10) or RA (ICD-9-CM 714 or ICD-10-CA M05 or M06). We calculated annual rates of hospitalizations (expressed per 100,000 Canadian adults) for gout and RA. We assessed the trend of total hip and knee replacements among study patients. We evaluated the inpatient economic burden for both conditions. Costs were inflation-adjusted to 2011 Canadian dollars. We assessed all annual trends using Poisson and linear regression models.

Results: From 2000 to 2011, the annual hospitalization rate for those with a principal diagnosis of RA declined by 49% from 15.4 to 7.9 per 100,000 Canadian adults (p<0.001), whereas that for gout increased by 100% (i.e., doubled) from 3.8 to 7.6 per 100,000 Canadian adults (p<0.001) (Figure). Thus, at the beginning of the study period, hospitalizations for RA were approximately 4 times more frequent than those for gout; however, these opposing trends of the two conditions led to similar hospitalization rates by 2011 (i.e., 7.9 and 7.6 per 100,000 Canadian adults for RA and gout, respectively). Approximately 31% of hospitalizations with a principal diagnosis of RA were associated with total hip or knee replacement. From 2000 to 2011, the rate of these surgeries in patients with a principal diagnosis of RA decreased from 3.8 to 2.9 per 100,000 Canadian adults (p=0.0097). In contrast, less than 1% of hospitalizations with a principal diagnosis of gout were associated with total hip or knee replacement. The inflation-adjusted inpatient costs associated with a principal diagnosis of gout more than doubled over the study period from $19,426 to $43,783 (2011 CAD) per 100,000 Canadian adults (p<0.001), whereas those for RA decreased by 40% from $103,314 to $62,348 per 100,000 Canadian adults (p=0.0023) over the same period.

Conclusion: Our findings indicate that hospitalization rates for gout have doubled over the past decade, while those for RA have decreased considerably. While these data provide an encouraging benchmark for RA care, they also highlight the critical need to improve gout management and prevention to mitigate its rising disease burden in Canada and beyond.


Disclosure: S. K. Rai, None; J. A. Avina-Zubieta, None; N. McCormick, None; M. A. De Vera, None; D. Lacaille, None; E. C. Sayre, None; H. K. Choi, None.

To cite this abstract in AMA style:

Rai SK, Avina-Zubieta JA, McCormick N, De Vera MA, Lacaille D, Sayre EC, Choi HK. Trends in Gout and Rheumatoid Arthritis Hospitalizations in Canada from 2000-2011 [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/trends-in-gout-and-rheumatoid-arthritis-hospitalizations-in-canada-from-2000-2011/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/trends-in-gout-and-rheumatoid-arthritis-hospitalizations-in-canada-from-2000-2011/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology